Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value
ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China Nation...
Ausführliche Beschreibung
Autor*in: |
Xingxing Li [verfasserIn] Zongjing Fan [verfasserIn] Jie Cui [verfasserIn] Dong Li [verfasserIn] Jinjin Lu [verfasserIn] Xiaoyun Cui [verfasserIn] Liandi Xie [verfasserIn] Yang Wu [verfasserIn] Qian Lin [verfasserIn] Yan Li [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Frontiers in Cardiovascular Medicine - Frontiers Media S.A., 2015, 9(2022) |
---|---|
Übergeordnetes Werk: |
volume:9 ; year:2022 |
Links: |
---|
DOI / URN: |
10.3389/fcvm.2022.817396 |
---|
Katalog-ID: |
DOAJ008040664 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ008040664 | ||
003 | DE-627 | ||
005 | 20230310003143.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fcvm.2022.817396 |2 doi | |
035 | |a (DE-627)DOAJ008040664 | ||
035 | |a (DE-599)DOAJd0f75980ec814cd581a71818f31b4e48 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC666-701 | |
100 | 0 | |a Xingxing Li |e verfasserin |4 aut | |
245 | 1 | 0 | |a Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 | ||
650 | 4 | |a heart failure | |
650 | 4 | |a trimethylamine N-oxide | |
650 | 4 | |a major adverse cardiovascular events | |
650 | 4 | |a all-cause mortality | |
650 | 4 | |a meta-analysis | |
653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
700 | 0 | |a Zongjing Fan |e verfasserin |4 aut | |
700 | 0 | |a Jie Cui |e verfasserin |4 aut | |
700 | 0 | |a Dong Li |e verfasserin |4 aut | |
700 | 0 | |a Jinjin Lu |e verfasserin |4 aut | |
700 | 0 | |a Xiaoyun Cui |e verfasserin |4 aut | |
700 | 0 | |a Liandi Xie |e verfasserin |4 aut | |
700 | 0 | |a Yang Wu |e verfasserin |4 aut | |
700 | 0 | |a Qian Lin |e verfasserin |4 aut | |
700 | 0 | |a Yan Li |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Frontiers in Cardiovascular Medicine |d Frontiers Media S.A., 2015 |g 9(2022) |w (DE-627)793951607 |w (DE-600)2781496-8 |x 2297055X |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2022 |
856 | 4 | 0 | |u https://doi.org/10.3389/fcvm.2022.817396 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48 |z kostenfrei |
856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2297-055X |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 9 |j 2022 |
author_variant |
x l xl z f zf j c jc d l dl j l jl x c xc l x lx y w yw q l ql y l yl |
---|---|
matchkey_str |
article:2297055X:2022----::rmtyaieoienerfiuemtaayio |
hierarchy_sort_str |
2022 |
callnumber-subject-code |
RC |
publishDate |
2022 |
allfields |
10.3389/fcvm.2022.817396 doi (DE-627)DOAJ008040664 (DE-599)DOAJd0f75980ec814cd581a71818f31b4e48 DE-627 ger DE-627 rakwb eng RC666-701 Xingxing Li verfasserin aut Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 heart failure trimethylamine N-oxide major adverse cardiovascular events all-cause mortality meta-analysis Diseases of the circulatory (Cardiovascular) system Zongjing Fan verfasserin aut Jie Cui verfasserin aut Dong Li verfasserin aut Jinjin Lu verfasserin aut Xiaoyun Cui verfasserin aut Liandi Xie verfasserin aut Yang Wu verfasserin aut Qian Lin verfasserin aut Yan Li verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 9(2022) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:9 year:2022 https://doi.org/10.3389/fcvm.2022.817396 kostenfrei https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48 kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 |
spelling |
10.3389/fcvm.2022.817396 doi (DE-627)DOAJ008040664 (DE-599)DOAJd0f75980ec814cd581a71818f31b4e48 DE-627 ger DE-627 rakwb eng RC666-701 Xingxing Li verfasserin aut Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 heart failure trimethylamine N-oxide major adverse cardiovascular events all-cause mortality meta-analysis Diseases of the circulatory (Cardiovascular) system Zongjing Fan verfasserin aut Jie Cui verfasserin aut Dong Li verfasserin aut Jinjin Lu verfasserin aut Xiaoyun Cui verfasserin aut Liandi Xie verfasserin aut Yang Wu verfasserin aut Qian Lin verfasserin aut Yan Li verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 9(2022) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:9 year:2022 https://doi.org/10.3389/fcvm.2022.817396 kostenfrei https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48 kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 |
allfields_unstemmed |
10.3389/fcvm.2022.817396 doi (DE-627)DOAJ008040664 (DE-599)DOAJd0f75980ec814cd581a71818f31b4e48 DE-627 ger DE-627 rakwb eng RC666-701 Xingxing Li verfasserin aut Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 heart failure trimethylamine N-oxide major adverse cardiovascular events all-cause mortality meta-analysis Diseases of the circulatory (Cardiovascular) system Zongjing Fan verfasserin aut Jie Cui verfasserin aut Dong Li verfasserin aut Jinjin Lu verfasserin aut Xiaoyun Cui verfasserin aut Liandi Xie verfasserin aut Yang Wu verfasserin aut Qian Lin verfasserin aut Yan Li verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 9(2022) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:9 year:2022 https://doi.org/10.3389/fcvm.2022.817396 kostenfrei https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48 kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 |
allfieldsGer |
10.3389/fcvm.2022.817396 doi (DE-627)DOAJ008040664 (DE-599)DOAJd0f75980ec814cd581a71818f31b4e48 DE-627 ger DE-627 rakwb eng RC666-701 Xingxing Li verfasserin aut Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 heart failure trimethylamine N-oxide major adverse cardiovascular events all-cause mortality meta-analysis Diseases of the circulatory (Cardiovascular) system Zongjing Fan verfasserin aut Jie Cui verfasserin aut Dong Li verfasserin aut Jinjin Lu verfasserin aut Xiaoyun Cui verfasserin aut Liandi Xie verfasserin aut Yang Wu verfasserin aut Qian Lin verfasserin aut Yan Li verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 9(2022) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:9 year:2022 https://doi.org/10.3389/fcvm.2022.817396 kostenfrei https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48 kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 |
allfieldsSound |
10.3389/fcvm.2022.817396 doi (DE-627)DOAJ008040664 (DE-599)DOAJd0f75980ec814cd581a71818f31b4e48 DE-627 ger DE-627 rakwb eng RC666-701 Xingxing Li verfasserin aut Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 heart failure trimethylamine N-oxide major adverse cardiovascular events all-cause mortality meta-analysis Diseases of the circulatory (Cardiovascular) system Zongjing Fan verfasserin aut Jie Cui verfasserin aut Dong Li verfasserin aut Jinjin Lu verfasserin aut Xiaoyun Cui verfasserin aut Liandi Xie verfasserin aut Yang Wu verfasserin aut Qian Lin verfasserin aut Yan Li verfasserin aut In Frontiers in Cardiovascular Medicine Frontiers Media S.A., 2015 9(2022) (DE-627)793951607 (DE-600)2781496-8 2297055X nnns volume:9 year:2022 https://doi.org/10.3389/fcvm.2022.817396 kostenfrei https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48 kostenfrei https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full kostenfrei https://doaj.org/toc/2297-055X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2022 |
language |
English |
source |
In Frontiers in Cardiovascular Medicine 9(2022) volume:9 year:2022 |
sourceStr |
In Frontiers in Cardiovascular Medicine 9(2022) volume:9 year:2022 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
heart failure trimethylamine N-oxide major adverse cardiovascular events all-cause mortality meta-analysis Diseases of the circulatory (Cardiovascular) system |
isfreeaccess_bool |
true |
container_title |
Frontiers in Cardiovascular Medicine |
authorswithroles_txt_mv |
Xingxing Li @@aut@@ Zongjing Fan @@aut@@ Jie Cui @@aut@@ Dong Li @@aut@@ Jinjin Lu @@aut@@ Xiaoyun Cui @@aut@@ Liandi Xie @@aut@@ Yang Wu @@aut@@ Qian Lin @@aut@@ Yan Li @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
793951607 |
id |
DOAJ008040664 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ008040664</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310003143.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fcvm.2022.817396</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ008040664</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd0f75980ec814cd581a71818f31b4e48</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xingxing Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P &lt; 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P &lt; 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trimethylamine N-oxide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">major adverse cardiovascular events</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">all-cause mortality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zongjing Fan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jie Cui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dong Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jinjin Lu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiaoyun Cui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liandi Xie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang Wu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qian Lin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yan Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Cardiovascular Medicine</subfield><subfield code="d">Frontiers Media S.A., 2015</subfield><subfield code="g">9(2022)</subfield><subfield code="w">(DE-627)793951607</subfield><subfield code="w">(DE-600)2781496-8</subfield><subfield code="x">2297055X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2022</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fcvm.2022.817396</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2297-055X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2022</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Xingxing Li |
spellingShingle |
Xingxing Li misc RC666-701 misc heart failure misc trimethylamine N-oxide misc major adverse cardiovascular events misc all-cause mortality misc meta-analysis misc Diseases of the circulatory (Cardiovascular) system Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value |
authorStr |
Xingxing Li |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)793951607 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC666-701 |
illustrated |
Not Illustrated |
issn |
2297055X |
topic_title |
RC666-701 Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value heart failure trimethylamine N-oxide major adverse cardiovascular events all-cause mortality meta-analysis |
topic |
misc RC666-701 misc heart failure misc trimethylamine N-oxide misc major adverse cardiovascular events misc all-cause mortality misc meta-analysis misc Diseases of the circulatory (Cardiovascular) system |
topic_unstemmed |
misc RC666-701 misc heart failure misc trimethylamine N-oxide misc major adverse cardiovascular events misc all-cause mortality misc meta-analysis misc Diseases of the circulatory (Cardiovascular) system |
topic_browse |
misc RC666-701 misc heart failure misc trimethylamine N-oxide misc major adverse cardiovascular events misc all-cause mortality misc meta-analysis misc Diseases of the circulatory (Cardiovascular) system |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Frontiers in Cardiovascular Medicine |
hierarchy_parent_id |
793951607 |
hierarchy_top_title |
Frontiers in Cardiovascular Medicine |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)793951607 (DE-600)2781496-8 |
title |
Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value |
ctrlnum |
(DE-627)DOAJ008040664 (DE-599)DOAJd0f75980ec814cd581a71818f31b4e48 |
title_full |
Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value |
author_sort |
Xingxing Li |
journal |
Frontiers in Cardiovascular Medicine |
journalStr |
Frontiers in Cardiovascular Medicine |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
author_browse |
Xingxing Li Zongjing Fan Jie Cui Dong Li Jinjin Lu Xiaoyun Cui Liandi Xie Yang Wu Qian Lin Yan Li |
container_volume |
9 |
class |
RC666-701 |
format_se |
Elektronische Aufsätze |
author-letter |
Xingxing Li |
doi_str_mv |
10.3389/fcvm.2022.817396 |
author2-role |
verfasserin |
title_sort |
trimethylamine n-oxide in heart failure: a meta-analysis of prognostic value |
callnumber |
RC666-701 |
title_auth |
Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value |
abstract |
ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 |
abstractGer |
ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 |
abstract_unstemmed |
ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208 |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value |
url |
https://doi.org/10.3389/fcvm.2022.817396 https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48 https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full https://doaj.org/toc/2297-055X |
remote_bool |
true |
author2 |
Zongjing Fan Jie Cui Dong Li Jinjin Lu Xiaoyun Cui Liandi Xie Yang Wu Qian Lin Yan Li |
author2Str |
Zongjing Fan Jie Cui Dong Li Jinjin Lu Xiaoyun Cui Liandi Xie Yang Wu Qian Lin Yan Li |
ppnlink |
793951607 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3389/fcvm.2022.817396 |
callnumber-a |
RC666-701 |
up_date |
2024-07-03T15:37:52.842Z |
_version_ |
1803572816479518720 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ008040664</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310003143.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fcvm.2022.817396</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ008040664</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd0f75980ec814cd581a71818f31b4e48</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xingxing Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ObjectiveThe present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF).MethodsPubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0.ResultsTen articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P &lt; 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P &lt; 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis.ConclusionElevated TMAO may be an adverse prognostic indicator in patients with HF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=267208</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trimethylamine N-oxide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">major adverse cardiovascular events</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">all-cause mortality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zongjing Fan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jie Cui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dong Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jinjin Lu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiaoyun Cui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liandi Xie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang Wu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qian Lin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yan Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Cardiovascular Medicine</subfield><subfield code="d">Frontiers Media S.A., 2015</subfield><subfield code="g">9(2022)</subfield><subfield code="w">(DE-627)793951607</subfield><subfield code="w">(DE-600)2781496-8</subfield><subfield code="x">2297055X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2022</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fcvm.2022.817396</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d0f75980ec814cd581a71818f31b4e48</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fcvm.2022.817396/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2297-055X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2022</subfield></datafield></record></collection>
|
score |
7.4018297 |